Email not displaying correctly? View it in your browser
Forward to a colleague | Sign up to BNF eNews
BNF BNF for Children Medicines Complete
May 2018 Share this issue Facebook LinkedIn Twitter
 
I Welcome
Welcome to the May BNF eNewsletter.
Nine new drug monographs have been added to the BNF/BNFC in the last month, chenodeoxycholic acid, lidocaine with cetrimide, tramadol with dexketoprofen, daptomycin, nilotinib, sofosbuvir, and sofosbuvir with ledipasvir.

This issue includes dose changes for abatacept, daptomycin, levonorgestrel, and nilotinib, as well as updated guidance on the management of cystic fibrosis, and osteoporosis. We have included MHRA advice on valproate medicines being contraindicated in women and girls of childbearing potential unless conditions of Pregnancy Prevention Programme are met and Esmya® (ulipristal acetate) for uterine fibroids about not initiating or re-starting treatment and monitoring liver function in current and recent users. You will also find NICE technology appraisals for daratumumab monotherapy for treating relapsed and refractory multiple myeloma and pirfenidone for treating idiopathic pulmonary fibrosis.
Kind regards,
BNF Team
I In this issue
BNF Publications Consultation More >  
MedicinesComplete is changing More >  
Significant changes More >  
News More >  
How to purchase BNF More >  
Drug safety update More >  
Feedback More >  
I BNF Publications Consultation - help us develop an even better resource
Consultation is a valuable step in the development of revised BNF Publications content. Periodically, the final draft version of selected BNF content will be available at www.bnf.org/consultation for open review by our users.

We are inviting healthcare professionals, interested groups and other users of BNF Publications to comment on and contribute to draft BNF Publications content. We'd like your views on our revised, draft content for the management of acute hypoglycaemia in children.

BNF 75 - BNFC 2017-2018
You'll be able to access the draft content from the 24th May until the 7th June 2018. We'll need to receive your review before midnight on the closing date.

Here's what we're looking for:

Objective and constructive feedback on the content's reflection of current practice
Comments on its representation of existing literature
The practicality of the recommendations
Any areas for consideration that are not currently addressed
Find out more about how to share your views with us here.

Your comments will help us make BNF Publications an even more valuable resource, so we welcome any feedback you can provide.

Thank you in advance for your contribution!
I Save the date! MedicinesComplete is changing on June 3rd
With the launch of the new MedicinesComplete experience for BNF users and switch-over to the new platform just around the corner, we encourage you to log in as soon as possible to get familiar with the changes.

You will continue to have access to the current MC platform until the 3rd of June 2018, when the legacy site will be retired. You may experience some temporary disruption in service on the 3rd and 4th of June whilst this change takes place and we do apologise for any inconvenience.

As previously highlighted, some of the additional publications may not be available immediately, however you will be notified as soon as they are released on the site.

Our team is here to help should you have any questions about the new platform.

Best wishes,
The MedicinesComplete team
I Significant changes
This month's changes to the clinical content of these publications are described in three parts:

BNF and BNFC update should be read by all users
BNF update should be read by all users of the BNF
BNFC update should be read by all users of the BNF for Children
BNF 72 - BNFC 2016-2017
BNF Update
Tramadol with dexketoprofen: new drug monograph
For further information, see tramadol with dexketoprofen.
Esmya® (ulipristal acetate) for uterine fibroids: do not initiate or re-start treatment; monitor liver function in current and recent users (MHRA advice)
For further information, see ulipristal acetate.
Dose changes
Daptomycin [update to dosing advice]
For further information, see daptomycin.
Nilotinib [update to dosing advice]
For further information, see nilotinib.
NICE technology appraisal update:
NICE technology appraisals that have been added to the BNF this month include:
Daratumumab monotherapy for treating relapsed and refractory multiple myeloma
Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma
Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
Pirfenidone for treating idiopathic pulmonary fibrosis
Sofosbuvir with velpatasvir and voxilaprevir for treating chronic hepatitis C
Other changes
To review other changes in BNF, click on changes.
BNF for Children Update
Daptomycin: new drug monograph
For further information, see daptomycin.
Nilotinib: new drug monograph
For further information, see nilotinib.
Sofosbuvir: new drug monograph
For further information, see sofosbuvir.
Ledipasvir with sofosbuvir: new drug monograph
For further information, see ledipasvir with sofosbuvir.
Dose changes
Lopinavir with ritonavir [update to age range]
For further information, see lopinavir with ritonavir.
Other changes
To review other changes in BNF for Children, click on changes.
BNF BNF for Children Update
Chenodeoxycholic acid: new drug monograph
For further information, see chenodeoxycholic acid.
Lidocaine with cetrimide: new drug monograph
For further information, see lidocaine with cetrimide.
Valproate medicines contraindicated in women and girls of childbearing potential unless conditions of Pregnancy Prevention Programme are met (MHRA advice)
For further information, see sodium valproate and valproic acid.
Head lice eradication products: risk of serious burns if treated hair is exposed to open flames or other sources of ignition (MHRA advice)
For further information, see skin infections.
Cystic fibrosis: updated guidance on management
For further information, see cystic fibrosis.
Dose changes
Abatacept [update to dosing advice]
For further information, see abatacept.
Levonorgestrel [update to timing for emergency contraception]
For further information, see levonorgestrel.
Levonorgestrel [update to effective duration for Levosert® intrauterine device]
For further information, see levonorgestrel.
I News
Valproate medicines: use in females of childbearing potential and during pregnancy - safety update
The MHRA has recently published strengthened recommendations for the use of valproate in girls and women of childbearing potential and during pregnancy. Valproate medicines are now contraindicated in girls and women of childbearing potential unless conditions of a Pregnancy Prevention Programme are met; they are also contraindicated for use during pregnancy unless there are no suitable alternatives for the treatment of epilepsy. The Valproate Pregnancy Prevention Programme is supported by materials produced by the Epilim® licence holder and by the MHRA; these will be sent to healthcare professionals shortly. For further information, see the Important safety information sections in the Sodium valproate and Valproic acid monographs in BNF and BNF for Children.
Use of topiramate in females of childbearing potential and during pregnancy
The advice for use of topiramate in pregnancy has recently been updated and information on its use in females of childbearing potential has been added, in line with changes to the Summary of Product Characteristics; see Pregnancy, and Conception and contraception in the Topiramate monograph.
Use of other drugs in females of childbearing potential and during pregnancy
Where appropriate, the BNF and BNF for Children include information around considerations for females of childbearing potential or men who might father a child in the Conception and contraception sections of individual monographs; advice on use of drugs during pregnancy is included in the Pregnancy sections of individual monographs. Content is regularly updated in line with changes made to Summaries of Product Characteristics and standard reference sources.
Presentation of Indication and dose sections in BNF Publications
Indication and dose information appears at the top of monographs and is highlighted by a coloured side panel online and by a coloured panel in print to aid quick reference. The Indication and dose section is highly structured, giving greater clarity around which doses should be used for which indications and by which route. In addition, where a dose varies with a specific preparation or formulation that dosing information appears in the indication and dose panel, under a heading of the preparation name. This can be seen in the Carbamazepine monograph - dosing information for modified-release preparations appears under the preparation name headings to ensure that prescribers select the correct doses for the specific preparations. For further information, see How to use BNF Publications online or How to use BNF Publications in print (BNF 75, page xii).
Reminder - help from CPPE with BNF 75
An interactive PDF e-learning programme from the Centre for Pharmacy Postgraduate Education (CPPE) will help you familiarise yourself with recommendations in BNF 75. It comprises 10 practical case studies that help you keep up to date with recent changes in the BNF, and can be accessed here.
BNF 74
I How to purchase BNF
Purchase Print copies
Purchase print copies
To order the March 2018 edition, visit the Pharmaceutical Press website.
More
Purchase a print subscription
Purchase a print subscription and save money
A print subscription is the best way to ensure access to the latest copy of BNF as soon as it publishes.
More
BNF online
BNF online
Outside the UK, content is available via a subscription to MedicinesComplete.
Email us
BNF eBook
BNF eBook
BNF is also available as a PDF eBook.
More
Drug Safety Update
Drug Safety Update is a monthly newsletter from
the MHRA and Commission on Human Medicine.
Please follow this link to review this month's Drug Safety Update.
I Feedback on our eNewsletter
Please let us know if there are any issues that you'd like us to address in our eNewsletters. We welcome your feedback. If you have any comments or suggestions, please let us know at marketing@rpharms.com.
Subscribe to this eNewsletter here
I Related Products
Medicines Complete BNF Pharmaceutical Press
BNF
Copyright © 2018 BMJ Publishing Group Ltd and the Royal Pharmaceutical Society of Great Britain. All rights reserved. Terms of use.
BNF for Children
Copyright © 2018 BMJ Publishing Group Ltd, the Royal Pharmaceutical Society of Great Britain and RCPCH Publications. All rights reserved. Terms of use.
If you do not wish to receive such mailings in the future please click here to unsubscribe.
Pharmaceutical Press, 66-68 East Smithfield, London, E1W 1AW, United Kingdom.